✦ LIBER ✦

Strategies in Selecting an Agent for Clinical Trials

✍ Scribed by RICHARD W. PECK

Book ID: 111392738
Publisher: John Wiley and Sons
Year: 1997
Tongue: English
Weight: 520 KB
Volume: 823
Category: Article
ISSN: 0890-6564
DOI: 10.1111/j.1749-6632.1997.tb48406.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Strategy for design of clinical trials o

Strategy for design of clinical trials of chemopreventive agents

✍ Stimson P. Schantz; Waun Ki Hong; Charles W. Boone; Gary J. Kelioff 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 108 KB

Merbarone: an antitumor agent entering c

Merbarone: an antitumor agent entering clinical trials

✍ Alice Glover; Hoo G. Chun; Larry M. Kleinman; David A. Cooney; Jacqueline Plowma 📂 Article 📅 1987 🏛 Springer US 🌐 English ⚖ 454 KB

Merbarone was developed to clinical trial stage on the basis of its 'curative' activity against P388 and L1210 leukemias and moderate activity against B16 melanoma and M5076 sarcoma. Its activity appears to be schedule-dependent favoring a longer duration of administration. The mechanism of action o

Design strategies in multiple sclerosis

Design strategies in multiple sclerosis clinical trials

✍ Dr George W. Ellison; Lawrence W. Myers; Barbara D. Leake; M. Ray Mickey; Dershi 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 506 KB

Candidate chemoprevention agents in clin

Candidate chemoprevention agents in clinical trials

✍ Waun Ki Hong 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB

New agents in cancer clinical trials

✍ Adams, Julian; Elliott, Peter J 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 127 KB

Development of gatekeeping strategies in

Development of gatekeeping strategies in confirmatory clinical trials

✍ Alex Dmitrienko; Brian A. Millen; Thomas Brechenmacher; Gautier Paux 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 254 KB